KYAN Technologies: Difference between revisions
Created page with "{{Draft}} {{Infobox Startup |logo=Kyan therapeutics logo.jpg |status=Active |website=https://kyantechnologies.com/ |vertical=Medtech, Biotechnology |trl=Deployment (TRL 7-8) |latest_funding=Pre-Series A |founding_year=2016 |headquarters=Singapore }} A brief overview of {{PAGENAME}} here ==Technology== Describe the underlying science and technology of the startup here. Ideally, it should provide a layman introduction of any key differentiators and/or novel or propriet..." |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Infobox Startup | {{Infobox Startup | ||
|logo=Kyan therapeutics logo.jpg | |logo=Kyan therapeutics logo.jpg | ||
| Line 10: | Line 9: | ||
|headquarters=Singapore | |headquarters=Singapore | ||
}} | }} | ||
KYAN Technologies is a Singapore-based startup that is developing a platform for [[precision medicine]] for both treatment and drug development in oncology. | |||
==Technology== | ==Technology== | ||
KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platform to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ different cancer types. | |||
The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models<ref>{{Cite web |title=Translational Biobank |url=https://kyantechnologies.com/translational-biobank/ |access-date=2025-12-20 |website=KYAN Technologies |language=en}}</ref>. | |||
==Traction== | ==Traction== | ||
KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web |last=admin |date=2023-05-29 |title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients |url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. Their facility is located in [[Temasek Life Science Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets. | |||
== | In February 2025, the startup announced a collaboration with OncoCare Malaysia to expand the use of KYAN Technologies' testing platform<ref>{{Cite web |last=admin |date=2025-02-05 |title=KYAN Technologies announces collaboration with OncoCare Malaysia |url=https://kyantechnologies.com/kyan-technologies-announces-collaboration-with-oncocare-malaysia/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. | ||
In March 2025, KYAN Technologies entered a collaboration with Mayo Clinic Laboratories to validate and provide the startup's testing platform across the United States<ref>{{Cite web |last=admin |date=2025-03-13 |title=Mayo Clinic Laboratories and KYAN Technologies enter a collaboration to expand patients’ access to cancer testing |url=https://kyantechnologies.com/mayo-clinic-laboratories-and-kyan-technologies-enter-a-collaboration-to-expand-patients-access-to-cancer-testing/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. | |||
==Funding== | ==Funding== | ||
KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web |last=Chong |first=Jinn Xiung |title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round |url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round |url-status=live}}</ref>{{Startup/Funding history}} | |||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
Latest revision as of 23:30, 20 December 2025
 | |
| Status | Active |
|---|---|
| Website | https://kyantechnologies.com/ |
| Vertical(s) | Medtech, Biotechnology |
| Latest Funding Round | Pre-Series A |
| Year founded | 2016 |
| Headquarters | Singapore |
| Technology Readiness Level | Deployment (TRL 7-8) |
KYAN Technologies is a Singapore-based startup that is developing a platform for precision medicine for both treatment and drug development in oncology.
Technology
KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platform to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy[1] across 20+ different cancer types.
The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models[2].
Traction
KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023[3]. Their facility is located in Temasek Life Science Laboratory. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets.
In February 2025, the startup announced a collaboration with OncoCare Malaysia to expand the use of KYAN Technologies' testing platform[4].
In March 2025, KYAN Technologies entered a collaboration with Mayo Clinic Laboratories to validate and provide the startup's testing platform across the United States[5].
Funding
KYAN Technologies raised US$5 million in pre-Series A funding from lead investor Altara Ventures in October 2022[6]
| Funding History | |
|---|---|
| Investor | Round |
| Altara Ventures | Pre-Series A |
| Seeds Capital | Pre-Series A |
| K3 Ventures | Pre-Series A |
Note: This list is community-maintained and may be incomplete or contain inaccuracies.
References
- ↑ "Optim.AI™ for Clinicians". KYAN Technologies. Retrieved 2025-12-20.
- ↑ "Translational Biobank". KYAN Technologies. Retrieved 2025-12-20.
- ↑ admin (2023-05-29). "Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients". KYAN Technologies. Retrieved 2025-12-20.
- ↑ admin (2025-02-05). "KYAN Technologies announces collaboration with OncoCare Malaysia". KYAN Technologies. Retrieved 2025-12-20.
- ↑ admin (2025-03-13). "Mayo Clinic Laboratories and KYAN Technologies enter a collaboration to expand patients' access to cancer testing". KYAN Technologies. Retrieved 2025-12-20.
- ↑ Chong, Jinn Xiung. "Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round".
{{cite web}}: CS1 maint: url-status (link)